FREE Account Opening + No Clearing Fees
Loading...
July 27, 2021 - July 29, 2021

Glenmark Life Sciences IPO Review & Recommendations

Anand Rathi, Ashika Research, Choice Equity Broking Pvt Ltd, Dolat Analysis and Research, GEPL Capital Ltd, ICICI Direct, Investmentz Ltd, Sushil Finance Ltd, InvestorGain.com and Ventura Securities Limited have given "Apply" recommendation to Glenmark Life Sciences IPO. Capital Market, Dilip Davda and SMC Global have given "May Apply" recommendation to Glenmark Life Sciences IPO. Axis Capital and HDFC Securities Limited have "Neutral" view about the IPO.

Glenmark Life Sciences IPO Review Summary from brokers and analysts

Review By Apply May Apply Neutral Avoid Not Rated
Count 10 3 2 0 0
% 66.67 20.00 13.33 0.00 0.00

Glenmark Life Sciences IPO Analysis By Brokers/Analysts

Glenmark Life Sciences IPO Capital Market Rating

The Captial Market (CapitalMarket.com) rating for Glenmark Life Sciences IPO is 48. Their analysis recommends May subscribe for the IPO.

Reviewer Rating Score Rating
Capital Market 48 May subscribe

Glenmark Life Sciences IPO Review by Dilip Davda (May apply)

[Dilip Davda]  Though this is a second public issue from Glenmark group after nearly two decades, it is encasing on the fancy of pharma segment amidst pandemic and hence the issue is fully priced discounting all near term positives. Considering the group's credentials and ongoing grey market activities the IPO may evoke a good response. Cash surplus investors may consider investing in this offer with a long term perspective. Read detail review...

Post Recommendation Manage Recommendations

Note:

  • The recommendations or analysis of public issues posted above expresses the views of its author and does not represent the views of Chittorgarh.com or its staff.
  • We reserve the right to remove any objectionable post without providing a reason.